Westfield Capital Management
GBT

Westfield Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Westfield Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-217,850
Closed -$12M – 271
2020
Q3 		$12M Sell
217,850
-13,098
-6% -$832K 0.08% 184
2020
Q2 		$14.6M Buy
230,948
+69,779
+43% +$4.79M 0.1% 185
2020
Q1 		$8.23M Buy
+161,169
New +$10.8M 0.07% 182

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management's GBT Position: Q4 2020 in Review

Westfield Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 217,850 shares — an estimated $12M sold.

Westfield Capital Management first reported a position in GBT in Q1 2020 and held it in 3 quarters. The position peaked at $14.6M in Q2 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • Westfield Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Westfield Capital Management sold 217,850 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $12M.
  • Westfield Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
  • Westfield Capital Management's Global Blood Therapeutics, Inc. position peaked at $14.6M in Q2 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Westfield Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.